Hepatitis Deaths Drop Amid Global Gains, But 2030 Goals Remain Elusive

By VirentaNews Staff — April 30, 2026

Every 23 seconds, someone dies from viral hepatitis—a disease that is both preventable and treatable. Despite decades of medical advances and global public health initiatives, hepatitis B and C claimed 1.34 million lives in 2024 alone, according to the latest World Health Organization (WHO) report released at the World Hepatitis Summit. While this marks a decline from previous peaks, the death toll remains stubbornly high, with more than 4900 new infections occurring daily. The report underscores a paradox: significant progress has been made in expanding antiviral treatments and infant vaccination coverage, yet these gains are unevenly distributed, leaving millions—particularly in low- and middle-income countries—without access to life-saving care. Without accelerated action, WHO warns, the global community will fall short of its 2030 goal to eliminate hepatitis as a public health threat.

Progress Amid Persistent Challenges

The global fight against hepatitis has seen notable milestones, including the widespread rollout of the hepatitis B vaccine in infant immunization programs, now reaching over 80% of newborns worldwide. Direct-acting antivirals (DAAs) for hepatitis C have transformed outcomes, offering cure rates exceeding 95% with short treatment courses. Yet, diagnostics and treatment access remain inadequate: only 12% of the estimated 354 million people living with chronic hepatitis B or C were diagnosed in 2024, and just 8% received treatment. The WHO attributes this gap to underfunded health systems, stigma, lack of awareness, and fragmented surveillance data. With the 2030 elimination targets—defined as a 90% reduction in new chronic infections and a 65% reduction in mortality—now less than six years away, the report stresses that current trajectories are insufficient to meet these benchmarks without urgent policy and financial intervention.

Regional Disparities and High-Burden Nations

The burden of viral hepatitis is not evenly distributed. Sub-Saharan Africa and East Asia bear the heaviest toll, with hepatitis B prevalence exceeding 5% in several countries. In contrast, high-income nations have seen dramatic declines due to universal vaccination, harm reduction programs, and widespread screening. In 2024, over 60% of new hepatitis infections occurred in just 11 countries, including Nigeria, India, and Pakistan, where health infrastructure struggles to keep pace with population growth and disease burden. Meanwhile, rising rates of hepatitis C among people who inject drugs in Western Europe and North America point to emerging challenges even in well-resourced settings. The report highlights that vertical transmission—from mother to child—remains a critical pathway for hepatitis B, yet fewer than 40% of eligible pregnant women received antiviral prophylaxis in high-prevalence regions. This patchwork of progress underscores the need for tailored, context-specific strategies rather than one-size-fits-all solutions.

Barriers to Diagnosis and Treatment Access

One of the most significant obstacles to eliminating hepatitis is the vast diagnostic gap. Most people with chronic hepatitis B or C are unaware of their status until they develop advanced liver disease, such as cirrhosis or hepatocellular carcinoma. The WHO identifies cost, lack of point-of-care testing, and insufficient healthcare workforce training as key bottlenecks. While generic versions of DAAs have slashed treatment prices—from over $80,000 per course in 2014 to under $50 in some countries—procurement challenges and regulatory delays still hinder distribution. In addition, stigma surrounding hepatitis, often linked to misconceptions about transmission through casual contact or association with drug use, deters individuals from seeking testing. Community-led initiatives and integration of hepatitis services into primary care and HIV programs have shown promise, but scaling these models requires sustained investment and political will.

Implications for Global Health Systems

The failure to accelerate hepatitis elimination has far-reaching consequences. Untreated chronic infections fuel a growing burden of liver disease, increasing strain on already overburdened health systems. Economically, the cost of managing advanced liver conditions far exceeds that of early treatment and prevention. Moreover, the overlap between hepatitis, HIV, and tuberculosis means that gaps in one program can undermine progress in others. Achieving the 2030 targets would not only save millions of lives but also strengthen health systems by improving diagnostic capacity, supply chains, and community engagement. Conversely, inaction risks entrenching inequities and missing a historic opportunity to eliminate a major infectious disease threat using existing tools.

Expert Perspectives

Experts are divided on the feasibility of meeting the 2030 targets. Dr. Philippa Easterbrook, WHO’s senior hepatitis advisor, emphasizes that “the tools are available—we now need the political commitment and financing to deploy them at scale.” Others, like Dr. Mark Harris, a virologist at the University of Edinburgh, caution that “without massive investment in screening and public education, we’re treating the tip of the iceberg.” Some analysts point to the success of Egypt’s national hepatitis C elimination campaign—which treated over 4 million people—as proof that rapid scale-up is possible with strong government leadership. Still, replicating such efforts globally remains a formidable challenge.

Looking ahead, the global community must prioritize integrated testing strategies, expand birth-dose vaccination coverage, and eliminate financial and social barriers to care. The upcoming 2025 UN High-Level Meeting on Pandemic Prevention offers a critical platform to mobilize resources and accountability. Whether the world can turn current momentum into transformative action will determine if the 2030 elimination goal remains within reach—or becomes another unmet promise in global health.

Source: WHO